June 20, 2024

Animal Model Market Size to Attain USD 5.72 Billion by 2033

The global animal model market size was valued at USD 2.48 billion in 2023 and is expected to rake around USD 5.72 billion by 2033, growing at a CAGR of 8.71% from 2024 to 2033.

Key Points

  • North America led the market with the largest market share of 50% in 2023.
  • By application type, the cancer segment has held the largest market share of 44% in 2023.
  • By animal type, the mice & rat segment held the largest share of 53% in 2023.
  • By end use, in 2023, the pharmaceutical & biotechnology companies segment has captured more than 40% of market share in 2023.

Animal Model Market Size 2024 to 2033

The Animal Model Market is a dynamic sector within the life sciences industry that plays a pivotal role in biomedical research. Animal models serve as indispensable tools for studying various diseases, understanding biological processes, and evaluating potential therapeutic interventions. These models, ranging from rodents to non-human primates, provide valuable insights into the complexities of human biology, offering a bridge between basic research and clinical applications. The market encompasses a wide array of applications, including drug development, disease modeling, and toxicity testing, making it a cornerstone for advancements in medicine and healthcare.

Get a Sample: https://www.precedenceresearch.com/sample/3890

Growth Factors

The Animal Model Market has experienced robust growth, driven by several key factors. Advances in genetic engineering technologies have allowed for the development of more sophisticated and precise animal models, enabling researchers to mimic specific genetic conditions and diseases accurately. The increasing demand for personalized medicine has also contributed to the expansion of this market, as researchers seek models that closely resemble human physiology for more accurate predictions of drug responses.

Moreover, the rise in chronic diseases and the need for effective treatments have intensified research activities, fuelling the demand for animal models in preclinical studies. Collaborations between pharmaceutical companies, academic institutions, and contract research organizations (CROs) have further accelerated market growth, fostering the sharing of resources and expertise in animal model development and experimentation.

Regions Snapshot

The Animal Model Market exhibits a global presence, with key regions playing vital roles in its development. North America stands as a major hub, driven by a well-established research infrastructure, substantial investments in biotechnology, and a high prevalence of pharmaceutical and biopharmaceutical companies. Europe follows closely, with significant contributions from countries like the United Kingdom, Germany, and France, owing to their strong research traditions and supportive regulatory frameworks.

The Asia-Pacific region has emerged as a rapidly growing market, propelled by increasing research activities, investments in healthcare infrastructure, and a rising focus on biopharmaceutical research in countries such as China and India. Latin America and the Middle East/Africa also contribute to the global landscape, with a growing awareness of the importance of animal models in biomedical research.

Animal Model Market Scope

Report CoverageDetails
Growth Rate from 2024 to 2033CAGR of 8.71%
Global Market Size in 2023USD 2.48 Billion
Global Market Size by 2033USD 5.72 Billion
U.S. Market Size in 2023USD 0.93 Billion
U.S. Market Size by 2033USD 2.15 Billion
Base Year2023
Forecast Period2024 to 2033
Segments CoveredBy Application, By Animal Type, and By End-use
Regions CoveredNorth America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

SWOT Analysis

Strengths: The Animal Model Market benefits from a well-established scientific foundation, with a rich history of contributions to medical breakthroughs. The versatility of animal models, allowing researchers to simulate complex human conditions, is a significant strength. Advanced technologies like CRISPR-Cas9 have enhanced the precision of genetic modifications in these models, making them invaluable in drug discovery and development.

Weaknesses: One of the primary weaknesses lies in the ethical considerations surrounding the use of animals in research. Animal welfare concerns, public scrutiny, and regulatory challenges pose ethical dilemmas for researchers and industry stakeholders. Additionally, the translatability of findings from animal models to humans is not always straightforward, leading to potential limitations in predicting human responses accurately.

Opportunities: The increasing prevalence of chronic diseases and the demand for personalized medicine present significant opportunities for the Animal Model Market. The development of novel models that closely mimic human physiology, combined with the integration of technologies such as organoids and humanized mice, opens new avenues for advancing preclinical research. Collaborations between academia and industry provide a platform for shared resources and expertise, fostering innovation.

Threats: Regulatory uncertainties and evolving ethical standards pose threats to the Animal Model Market. Stringent regulations and growing public awareness of animal rights may impact the availability and use of certain animal models. Additionally, the development of alternative in vitro models and computational approaches poses a potential threat, challenging the traditional reliance on animal models in research.

Read Also: Recombinant Antibodies Market Size to Cross USD 23.34 Bn by 2033

Recent Developments

  • In September 2022, Solid Biosciences announced its acquisition of AavantiBio alongside a concurrent $75 million private placement.
  • In April 2023, Merck bolstered its immunology pipeline with the acquisition of Prometheus Biosciences, Inc.
  • In February 2023, AstraZeneca successfully completed the acquisition of CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease.
  • In August 2023, Biocytogen established two business divisions to distinguish preclinical models and Services (BioMice) from antibody-drug R&D.

Animal Model Market Companies

  • Charles River Laboratories
  • The Jackson Laboratory
  • genOway
  • Taconic Biosciences, Inc.
  • Janvier Labs
  • Harbour BioMed
  • Crown Bioscience
  • Inotiv
  • BIOCYTOGEN
  • BioSpherix, Ltd.

Segments Covered in the Report

By Application

  • Cancer
  • Immunological Disease
  • Infectious Disease
  • Others

By Animal Type

  • Mice
  • Rat
  • Guinea Pigs
  • Rabbits
  • Hamsters
  • Others

By End-use

  • Pharmaceutical & Biotechnology Companies
  • Academic Research Institute
  • Contract Research Organization

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa